Pfizer recently concluded its stake sale in Haleon, netting around $3.3 billion. This finalizes Pfizer's exit from Haleon, marking a significant change in the ownership structure of the consumer healthcare giant. Haleon has simultaneously been executing a share buyback, cancelling 44 million shares. The company's top executives have been awarded shares under a reward plan, marking a move to strengthen its leadership structure. This action, coupled with Pfizer's stake sale, has been closely monitored in the biotech market. Interestingly, Haleon's performance in the face of these changes has been reportedly positive as analysts such as Jim Cramer notes. However, the focus is also on Pfizer and its motives for the complete divestment. Gauging the potential impacts on Haleon's performance, institutional owners currently hold 77% of Haleon, signalling a level of confidence in the company's outlook.
Haleon Stocks News Analytics from Wed, 28 Aug 2024 07:00:00 GMT to Sat, 22 Mar 2025 00:19:29 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -6
